SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1532343
This article is part of the Research TopicCommunity Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy: Volume IIIView all 13 articles
Prognostic value of the Systemic Immune-Inflammation Index in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Provisionally accepted
- 1Lanzhou University Medical College, Lanzhou, Gansu, China
- 2Department of Respiratory and Critical Care Medicine, The First Hospital of Lanzhou University, LanZhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Although the systemic immune-inflammation index (SII) has emerged as a potential prognostic marker in various cancers, its specific role in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy remains insufficiently explored. To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors (ICIs). Method A comprehensive search was conducted across multiple databases-including PubMed, EMBASE, Cochrane and Web of Science-to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of SII for survival outcomes.Ten studies involving a total of 1,547 patients were included. High systemic immuneinflammation index (SII) was significantly associated with worse overall survival (OS) (HR=1.44, 95% CI=1.21-1.70, p < 0.001; I²=3.8%) and progression-free survival (PFS) (HR=1.44, 95% CI=1.21 -1.71, p < 0.001; I²=37.2%). Subgroup analysis indicated that an SII >792 was significantly associated with poorer OS and PFS.High SII is significantly associated with poorer OS and PFS, particularly when SII ＞ 792.
Keywords: systemic immune-inflammation index, Non-small cell lung cancer, immune checkpoint inhibitors, Survival, Meta-analysis
Received: 21 Nov 2024; Accepted: 28 Apr 2025.
Copyright: © 2025 Chen, Bao, Ye, Hu, Sun and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Weiying Liu, Department of Respiratory and Critical Care Medicine, The First Hospital of Lanzhou University, LanZhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.